All In Biotech

Drug Trial Radar · NCT05177666

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

Patients With Advanced Refractory Solid Tumors Who Failed Standard Treatments and Matched Individualized Treatment Based on Tumor Molecular Characteristics: a Prospective Registration Study

Last checked: Nov 20, 2026Latest source record: Jan 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

120

Planned (sponsor's estimate)

Start

Dec 30, 2021

Primary completion

Dec 30, 2023

Study completion Mar 30, 2024

Sponsor

Lead sponsor
The University of Hong Kong-Shenzhen HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Tianjin Happy Life Technology Co., Ltd.
First posted
Jan 4, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

This is a prospective registration study for patients with advanced refractory solid tumors. Patients who meet the eligibility criteria will be included to participate in the study, and baseline information to be collected after signed informed consent. Patients will choose for themselves whether to carry out targeted therapy or other appropriate treatment methods. And we plan to follow up for at least 12 months or until disease progression or death.

Conditions

  • Feasibility
  • Effectiveness
  • Safety
  • Targeted Molecular Therapy

Interventions

  • Targeted therapyDrug

    Based on next-generation sequencing (NGS) detection, after discussion by the Molecular Steering Committee (MTB), intervention guidance suggestions are given based on domestic and foreign guidelines and clinical experience, and finally the patient and clinician jointly choose the treatment plan.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: 2021.11-2023.11
  2. Proportion of targeted therapy guided by tumor molecular characteristicsTime frame: 2021.11-2023.11

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.